Serum and cerebral spinal fluid levels of chemokines and Th2 cytokines in Schistosoma mansoni myeloradiculopathy

Parasite Immunology

Volumn 28, Issue 9, 2006, Pages 473-478

  Sousa Pereira, S R ^a   Teixeira, A L ^a   Silva, L C S ^a   Souza, A L S ^a   Antunes, C M ^a   Teixeira, M M ^a   Lambertucci, J R ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Chemokines; Cytokines; Myeloradiculopathy; Neuroschistosomiasis; Schistosomiasis

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CCR3; CYTOKINE; EOTAXIN; EOTAXIN 2; INTERLEUKIN 13; INTERLEUKIN 4; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD ANALYSIS; CELLULAR IMMUNITY; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; IMMUNOREACTIVITY; MALE; MYELORADICULOPATHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SCHISTOSOMA MANSONI; SCHISTOSOMAL MYELORADICULOPATHY; SPINAL CORD LESION; TH2 CELL;

ADOLESCENT; ADULT; ANIMALS; CHEMOKINES; CYTOKINES; FEMALE; HUMANS; MALE; NEUROSCHISTOSOMIASIS; SCHISTOSOMA MANSONI; TH2 CELLS;

SCHISTOSOMA MANSONI;

EID: 33747309064     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/j.1365-3024.2006.00896.x     Document Type: Article

References (22)

1. Silva LC, Maciel PE, Ribas JG et al. Schistosomal myeloradiculopathy. Rev Soc Bras Med Trop 2004; 37: 261-272.
2. Carod Artal FJ, Vargas AP, Horan TA, Marinho PB & Coelho Costa PH. Schistosoma mansoni myelopathy: clinical and pathologic findings. Neurology 2004; 63: 388-391.
3. Nobre V, Silva LC, Ribas JG et al. Schistosomal myeloradiculopathy due to Schistosoma mansoni: report on 23 cases. Mem Inst Oswaldo Cruz 2001; 96: 137-141.
4. Camargos ST, Dantas FR & Teixeira AL. Schistosomal myelopathy mimicking spinal cord neoplasm. Scand J Infect Dis 2005; 37: 365-367.
5. Lambertucci JR, Serufo JC, Gerspacher-Lara R et al. Schistosoma mansoni: assessment on morbidity before and after control. Acta Trop 2000; 77: 101-109.
6. Silva LC, Maciel PE, Ribas JG, Souza-Pereira SR, Antunes CM & Lambertucci JR. Treatment of schistosomal myeloradiculopathy with praziquantel and corticosteroids and evaluation by magnetic resonance imaging: a longitudinal study. Clin Infect Dis 2004; 39: 1618-1624.
7. Centers for Disease Control. Acute schistosomiasis with transverse myelitis in American students returning from Kenya. MMWR Morb Mortal Wkly Rep 1984; 33: 445-447.
8. Pittella JE. Neuroschistosomiasis. Brain Pathol 1997; 7: 649-662.
9. Pearce EJ. Priming of the immune response by schistosome eggs. Parasite Immunol 2005; 27: 265-270.
10. Ross AG, Bartley PB, Sleigh AC et al. Schistosomiasis. N Engl J Med 2002; 344: 1212-1220.
11. Falcão PL, Corrêa-Oliveira R, Fraga LA et al. Plasma concentrations and role of macrophage inflammatory protein-1α during chronic Schistosoma mansoni infection in humans. J Infect Dis 2002; 186: 1696-1700.
12. Souza AL, Roffê E, Pinho V et al. Potential role of chemokine macrophage inflammatory protein-1α in human and experimental schistosomiasis. Infect Immun 2005; 73: 2515-2523.
13. Ransohoff RM. The chemokine system in neuroinflammation: an update. J Infect Dis 2002; 186 (Suppl. 2): S152-S156.
14. Secor WE. Immunology of human schistosomiasis: off the beaten path. Parasite Immunol 2005; 27: 309-316.
15. Katz N, Chaves A & Pellegrino J. A simple device for quantitative stool thick-smear technique in Schistosoma mansoni. Rev Inst Med Trop Sao Paulo 1972; 14: 397-400.
16. Teixeira AL, Cardoso F, Souza ALS & Teixeira MM. Increased serum concentrations of monokine induced by interferon-γ/CXCL9 and interferon-γ-inducible protein 10/CXCL-10 in Sydenham's chorea patients. J Neuroimmunol 2004; 150: 157-162.
17. Sorensen TL, Tani M, Jensen J et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999; 103: 807-815.
18. Trebst C & Ransohoff RM. Investigating chemokines and chemokine receptors in patients with multiple sclerosis: opportunities and challenges. Arch Neurol 2001; 58: 1975-1980.
19. Proudfoot AE, Handel TM, Johnson Z et al. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci USA 2003; 100: 1885-1990.
20. Kieseier BC, Tani M, Mahad D et al. Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. Brain 2002; 125: 823-834.
21. Narikawa K, Fujihara K, Misu T et al. CSF chemokines in HTLV-1 associated myelopathy: CXCL10 up-regulation and therapeutic effect of interferon-α. J Neuroimmunol 2005; 159: 177-182.
22. Zimmermann N, Hershey GK, Foster PS & Rothenberg ME. Chemokines in asthma: cooperative interaction between chemokines and IL-13. J Allergy Clin Immunol 2003; 111: 227-242.